19 October 2020: Clinical Research
Roles of Morris Index on Poor Outcomes in Patients with Non-ST Segment Elevation Acute Coronary Syndrome
Huizhong Lin 1AE , Tao Lin 2BC , Lan Lin 1DF , Mingfang Ye 1AG*DOI: 10.12659/MSM.924418
Med Sci Monit 2020; 26:e924418
Table 1 The characteristics of NSTE-ACS patients in the four groups.
| Variables | PTFV1 (−)/(−)(n=563) | PTFV1 (−)/(+)(n=97) | PTFV1 (+)/(−)(n=98) | PTFV1 (+)/(+)(n=147) |
|---|---|---|---|---|
| Gender, n (%) | ||||
| Male | 409 (72.6) | 64 (66.0) | 69 (70.4) | 118 (80.3) |
| Female | 154 (27.4) | 33 (34.0) | 29 (29.6) | 29 (19.7) |
| Age, years, mean±SD | 67.25±10.16 | 68.93±9.28 | 69.83±10.36 | 68.39±10.51 |
| Smoking, n (%) | ||||
| Yes | 224 (39.8) | 39 (40.2) | 33 (33.7) | 62 (42.2) |
| No | 339 (60.2) | 58 (59.8) | 65 (66.3) | 85 (57.8) |
| Hypertension, n (%) | ||||
| Yes | 362 (64.3) | 65 (67.0) | 64 (65.3) | 111 (75.5) |
| No | 201 (35.7) | 32 (33.0) | 34 (34.7) | 36 (24.5) |
| Diabetes, n (%)* | ||||
| Yes | 153 (27.2) | 40 (41.2) | 34 (34.7) | 48 (32.7) |
| No | 410 (72.8) | 657 (58.8) | 64 (65.3) | 99 (67.3) |
| Cerebral ischemic stroke, n (%) | ||||
| Yes | 50 (8.9) | 12 (12.4) | 15 (15.3) | 14 (9.5) |
| No | 513 (91.2) | 85 (87.6) | 83 (84.7) | 133 (90.5) |
| PCI/CABG, n (%) | ||||
| Yes | 436 (77.4) | 70 (72.2) | 76 (77.6) | 106 (72.1) |
| No | 127 (22.6) | 27 (27.8) | 22 (22.4) | 41 (27.9) |
| SBP, mmHg, mean±SD | ||||
| Admission | 133.4±19.0 | 135.5±19.0 | 136.7±22.9 | 135.4±19.7 |
| Discharge | 125.0±13.1 | 6126.7±13.7 | 125.0±12.7 | 126.4±14.2 |
| DBP, mmHg, mean±SD | ||||
| Admission | 79.4±10.8 | 78.5±10.7 | 78.7±10.2 | 79.0±12.1 |
| Discharge | 74.4±8.0 | 75.0±8.1 | 74.0±7.6 | 75.3±8.8 |
| HR, beats/min, mean±SD | ||||
| Admission | 71.8±10.2 | 72.9±11.9 | 72.9±10.2 | 74.1±9.9 |
| Discharge | 69.8±6.6 | 669.9±7.3 | 69.6±5.6 | 70.4±6.9 |
| GRACE score, M(Q25, Q75) | ||||
| Admission* | 126.0 (104.0, 152.0) | 138.0 (121.0, 168.5)a | 139.0 (125.0, 165.0)a | 151.5 (129.0, 177.0)a |
| Discharge* | 101.0 (88.0, 115.0) | 116.0 (95.0, 135.5)a | 108.0 (94.0, 125.0)a | 113.0 (100.0, 127.0)a |
| EF, %, mean±SD* | 63.5±9.5 | 59.4±12.5 | 59.5±12.0 | 56.3±15.1 |
| LA, mm, mean±SD* | 34.2±4.6 | 36.0±5.7 | 35.5±4.7 | 38.4±5.5 |
| LDL, mmol/L, mean±SD | 2.85±1.13 | 2.98±1.12 | 2.86±1.17 | 2.75±1.10 |
| Statins, n (%) | ||||
| Yes | 524 (93.1) | 86 (88.7) | 91 (92.86) | 138 (93.9) |
| No | 39 (6.9) | 11 (11.3) | 7 (7.14) | 9 (6.1) |
| β-receptor blocker, n (%) | ||||
| Yes | 357 (63.4) | 60 (61.9) | 71 (72.5) | 91 (61.9) |
| No | 206 (36.6) | 37 (38.1) | 27 (27.5) | 56 (38.1) |
| ACEI/ARB, n (%) | ||||
| Yes | 319 (56.7) | 60 (61.9) | 61 (62.2) | 101 (68.7) |
| No | 244 (43.3) | 37 (38.1) | 37 (37.8) | 46 (31.3) |
| Aspirin, n (%) | ||||
| Yes | 521 (92.5) | 89 (91.8) | 88 (89.8) | 131 (89.1) |
| No | 42 (7.5) | 8 (8.2) | 10 (10.2) | 16 (10.9) |
| Ticagrelor/Clopidogrel, n (%) | ||||
| Yes | 513 (91.1) | 85 (87.6) | 93 (94.9) | 138 (93.9) |
| No | 50 (8.9) | 12 (12.4) | 5 (5.1) | 9 (6.1) |
| CCB, n (%) | ||||
| Yes | 113 (20.1) | 27 (27.8) | 30 (30.6) | 37 (25.2) |
| No | 450 (79.9) | 70 (72.2) | 68 (69.4) | 110 (74.8) |
| Diuretics, n (%) | ||||
| Yes | 119 (21.1) | 18 (18.6) | 24 (24.5) | 41 (27.9) |
| No | 444 (78.9) | 79 (81.4) | 74 (75.5) | 106 (72.1) |
| Total poor outcomes, n (%)* | 35 (6.2) | 25 (25.8) | 7 (7.1) | 18 (9.4) |
| MACE* | 28 (4.9) | 24 (24.7) | 6 (6.1) | 16 (10.1) |
| Cerebral ischemic stroke | 2 (0.4) | 0 (0) | 1 (1.0) | 1 (0.7) |
| Other causes of death | 5 (0.9) | 1 (1.0) | 0 (0) | 1 (0.7) |
| * a: compared with PTFV1 (−)/(−), NSTE-ACS – non-ST segment elevation acute coronary syndrome; PCI – percutaneous coronary intervention; CABG – coronary artery bypass grafting; SBP – systolic blood pressure; DBP – diastolic blood pressure; HR – heart rate; PTFV1 – p-wave terminal force in lead V1; GRACE – Global Registry of Acute Coronary Event; EF – ejection fraction; LA – left atrium; LDL – low density lipoprotein; ACEI – angiotensin converting enzyme inhibitors; ARB – angiotensin receptor blocker; CCB – calcium channel blockers; MACE – major adverse cardiovascular events. | ||||